Mantle Cell Lymphoma Survival Predictor Using FFPE RNA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting the prognosis of mantle cell lymphoma (MCL) are inconsistent and lack reproducibility due to inter-laboratory and inter-observer variability, particularly with the Ki-67 proliferation index, and require fresh frozen tissue, limiting their clinical applicability.
Innovation Solution
A method involving the isolation of RNA gene expression products from biopsy samples, followed by determination of a survival predictor score using specific gene expression data and coefficients, allowing for classification into good, intermediate, or poor prognosis groups, even with formalin-fixed paraffin-embedded tissue, using the NanoString Technologies platform.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If Ki-67 proliferation index is used for prognosis prediction, then prognosis assessment can be obtained, but inter-laboratory and inter-observer variability reduces measurement precision and reliability
Solution Approach 1:
The patent replaces manual immunohistochemistry scoring (mechanical/visual assessment) with automated image analysis software that objectively quantifies Ki-67 staining. This substitution eliminates inter-observer variability by using computer algorithms instead of human pathologists to calculate proliferation indices, thereby improving measurement precision and reliability simultaneously
Solution Approach 2:
The patent introduces digital image processing and automated analysis software as an intermediary between tissue sample assessment and prognosis prediction. This intermediary layer standardizes the measurement process across different laboratories, reducing variability while maintaining the ability to generate prognostic assessments
2Measurement precision
If microarray-based gene expression profiling is used, then proliferation signature can be obtained, but requirement for fresh frozen tissue limits clinical applicability
Solution Approach 1:
The patent changes the tissue preparation parameter from fresh frozen to formalin-fixed paraffin-embedded (FFPE) preservation method. This parameter change enables the use of routine clinical tissue samples while maintaining gene expression profiling capability through modified molecular techniques that work with fixed tissue, thereby improving clinical applicability without sacrificing measurement precision
Solution Approach 2:
The patent creates a surrogate proliferation signature using gene expression data from FFPE tissues that replicates the information obtained from fresh frozen tissues. This copying approach allows clinical laboratories to obtain accurate proliferation assessments using readily available fixed tissue samples instead of requiring specialized fresh frozen processing
3Ease of operation
If gene expression-based assays are developed using FFPE tissue, then clinical relevance is improved, but reproducibility and consistency need enhancement
Solution Approach 1:
The patent develops a universal gene expression assay that works consistently across different FFPE tissue samples from various clinical sources. The assay uses a standardized panel of proliferation-related genes with normalized expression scoring that produces reproducible results regardless of the specific laboratory or patient sample, thereby achieving both clinical relevance and measurement precision
Solution Approach 2:
The patent implements standardized parameters for RNA extraction, gene expression measurement, and data normalization specific to FFPE tissues. These controlled parameter changes ensure that assays performed in different clinical laboratories yield consistent and reproducible proliferation signatures, enhancing score reliability while maintaining clinical applicability
Data Source
AI summary
The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.